Enabling Technologies

This alliance performs world leading research that applies the latest advances in manufacturing, material sciences, analytical and digital technologies to pharmaceutical sciences as well as in Pharmacy through cross-disciplinary work with the Medicines Use research group. Our goal in this area is to solve current challenges in the areas of personalised medicine, age-appropriate medicines and point-of-care diagnostics by connecting Pharmacy to an increasingly smart and digitally connected environment of this age. The alliance has expertise in 3D printing in healthcare and in material sciences, nanofabrication technology such as electrohydrodynamic atomization and electrospinning, microfluidics with expertise in “lab on chip” functionality, and nanofabrication technology.

Advancing Electromagnetic hyperthermic medical technologies

The Raimi-Abraham Group

Pharmaceutical Formulation and Analysis

The focus of this group is to use advances in pharmaceutical science to develop dosage forms which offer more superior behaviour than conventional formulations. These advanced formulations can improve the bioavailability of drugs and reduce side effects. Combined with this, the group secures an understanding the interactions between drugs (small or macromolecular drugs) and the pharmaceutical excipients through the combined application of advanced analytical techniques, including thermal analysis, mechanical properties and stability testing, computer modelling, FT-IR, circular dichroism, Raman spectroscopy, static and dynamic light scattering, rheometry and dilute solution viscometry, atomic force microscopy, X-ray diffraction, small angle neutron scattering, neutron reflectivity and both liquid and solid-state NMR. This work is applied in both the kinetic and equilibrated states to health-related fields, drug disposition and metabolism.

Delivery across Biological Barriers

This group perform research and development in pharmaceutical technology and apply scientific principles to the formulation of medicines and in the development and use of experimental models of drug absorption. This involves not only some of the more challenging conventional drug molecules, but also the products of biotechnology. The group studies drug delivery across different biological barriers including oral and respiratory drug absorption, microbial biofilms and the microbiome, delivery of chemicals into and extraction of biomarkers from the skin, plus drug penetration across the blood brain barrier. The targeting of antimicrobials to bacteria involves similar challenges. The ability of a formulation to influence the targeting and duration of drug action and affect therapeutic success is the major theme and results in a multifaceted research programme.

Inhaled Medicines

Understanding Gastrointestinal Absorption-related Processes

Vllasaliu Lab

Theragnostic Nanomedicines

The group is pioneering novel nanoscale formulations and materials for healthcare applications. Purpose designed nanoparticles are prepared, analysed and developed using prototype materials and methods that range from chemical synthesis to bioimaging and disease models. Emphasis is given in modifying biological nanocarriers and/or synthesis of biomimetic nanoparticles. Nanomedicines are prepared to target the brain for imaging and therapy, for oral delivery for mucosal disease treatment, dental applications for remineralisation of lesions, for the early detection, imaging and therapy of several tumour types. The group has expertise in exosomes, carbon nanomaterials, magnetic nanoparticles, triggerable liposomes, image guided drug delivery, focused ultrasound drug delivery, and nanoparticles that respond to electromagnetic radiation.

Cancer Nanomedicine - from the bench to the bedside

London Institute of Advanced Light Technologies

British Society of Nanomedicine

APSGB (nanomedicines focus group)

London Centre for Nanotechnology

Centre for Pharmaceutical Medicine Research

The group have an overarching aim of improving the process of developing medicines for human use. This is achieved through three main areas of research: (i) Patient Centric Medicine Development (ii) Improving Access to Medicines, (iii) Improving Clinical Trial Efficiency. The group have strong links with the Faculty of Pharmaceutical Medicine (FPM), the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP, drug development scientists, clinical pharmacologists and the pharmaceutical industry. People: Dr Stuart Jones Dr Mohamed Alhnan Dr Caroline Copeland Emily Robinson Professor Albert Ferro Professor Clive Page Professor John Posner David Morgan Professor Bams Abila Carl Naraynassamy Professor Peter Stonier Dr Tony Lockett Professor Graham McClelland Dr Neil Snowise Dr John Bolodeoku Dr Paul Rees

King's Health Partners

Pharmaceutical Sciences Clinical Academic Group

PhD projects

As a PhD student you would be expected to participate actively in regular research seminars and journal club meetings and will be invited to deliver some teaching as appropriate. Before you apply online for a PhD, please contact individual group members to find out whether they are available and discuss potential projects. Our PhD student cohort is highly international, and includes students with scholarships from their own countries, UK research council funding or doctoral training schemes in partnership with the pharmaceutical industry.